# EDGAR Filing Document

**Accession Number:** 0001586554
**File Stem:** 0001104659-26-062758
**Filing Date:** 2026-5
**Character Count:** 115210
**Document Hash:** 0b3251dfa0281381da870c97c13407ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-062758.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001104659-26-062758

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 73

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Target Group Inc.
- **CENTRAL INDEX KEY:** 0001586554
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463610035
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55066
- **FILM NUMBER:** 26989394

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 20 HEMPSTEAD DRIVE
- **CITY:** HAMILTON
- **PROVINCE COUNTRY:** A6
- **ZIP:** L8W 2E7
- **BUSINESS PHONE:** 905-541-3833

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 55 ADMINISTRATION ROAD, UNIT 13
- **CITY:** VAUGHAN
- **PROVINCE COUNTRY:** A6
- **ZIP:** L4K-4G9

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chess Supersite Corp
- **DATE OF NAME CHANGE:** 20140513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** River Run Acquisition Corp
- **DATE OF NAME CHANGE:** 20130911

?xml version='1.0' encoding='ASCII'? TARGET GROUP INC._March 31, 2026

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| For the quarterly period ended March 31, 2026 | For the quarterly period ended March 31, 2026 |
| or | or |
| ☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Commission file number: 000-55066

**TARGET GROUP INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **46-3621499** |
| (State or Other Jurisdiction of<br>Incorporation or Organization) | (I.R.S. Employer<br>Identification No.) |
| **20 Hempstead Drive**<br>**Hamilton, Ontario, Canada** | **L8W 2E7** |
| (Address of principal executive officers) | (Zip Code) |

---

**+1 905-541-3833**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered under Section 12(b) of the Act:

None

Securities registered under Section 12(g) of the Act:

Common Stock, Par Value $0.0001

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "small reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter was $4,627,695 as of June 30, 2025.

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: As of May 15, 2026, the registrant had 617,025,999 shares of Common Stock issued and outstanding.

------

[**Table of Contents**](#TOC)

#### **TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| [PART I – FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_313640) | [PART I – FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_313640) |  |
| [Item 1.](#ITEM1UNAUDITEDCONDENSEDCONSOLIDATEDINTER) | [Condensed Consolidated Interim Financial Statements (Unaudited)](#ITEM1UNAUDITEDCONDENSEDCONSOLIDATEDINTER) | 3 |
| [Item 2.](#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF) | 4 |
| [Item 3.](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | [Quantitative and Qualitative Disclosures About Market Risk](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | 9 |
| [Item 4.](#ITEM4CONTROLSANDPROCEDURES_962104) | [Controls and Procedures](#ITEM4CONTROLSANDPROCEDURES_962104) | 9 |
| [PART II – OTHER INFORMATION](#PARTIIOTHERINFORMATION_406682) | [PART II – OTHER INFORMATION](#PARTIIOTHERINFORMATION_406682) |  |
| [Item 1.](#ITEM1LEGALPROCEEDINGS_872995) | [Legal Proceedings](#ITEM1LEGALPROCEEDINGS_872995) | 10 |
| [Item 2.](#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES) | [Unregistered Sales of Equity Securities and Use of Proceeds](#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES) | 10 |
| [Item 3.](#ITEM3DEFAULTSUPONSENIORSECURITIES_368292) | [Defaults Upon Senior Securities](#ITEM3DEFAULTSUPONSENIORSECURITIES_368292) | 10 |
| [Item 4.](#ITEM4MINESAFETYDISCLOSURES_899757) | [Mine Safety Disclosures](#ITEM4MINESAFETYDISCLOSURES_899757) | 10 |
| [Item 5.](#ITEM5OTHERINFORMATION_814884) | [Other Information](#ITEM5OTHERINFORMATION_814884) | 10 |
| [Item 6.](#ITEM6EXHIBITS_19745) | [Exhibits](#ITEM6EXHIBITS_19745) | 11 |

---

[**Table of Contents**](#TOC)

#### PART I – FINANCIAL INFORMATION

#### ITEM 1. UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS.

#### TARGET GROUP INC.

#### UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

#### INDEX

---

| | |
|:---|:---|
| [Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025](#CONDENSEDCONSOLIDATEDBALANCESHEETS_91874) | F-1 |
| [Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025 (Unaudited)](#COMPREHENSIVELOSS_876110) | F-2 |
| [Condensed Consolidated Statements of Stockholders' Deficit for the three months ended March 31, 2026 and 2025 (Unaudited)](#STOCKHOLDERSDEFICIT_717510) | F-3 |
| [Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (Unaudited)](#STATEMENTSOFCASHFLOWS_697700) | F-5 |
| [Notes to Condensed Consolidated Interim Financial Statements (Unaudited)](#a1OrganizationNatureofBusinessGoingConce) | F-6 - F-19 |

---

[**Table of Contents**](#TOC)

#### TARGET GROUP INC.

#### CONDENSED CONSOLIDATED BALANCE SHEETS

---

| | | | |
|:---|:---|:---|:---|
|  |  | **March 31,** <br>**2026**<br>**$** | **December 31,** <br>**2025**<br>**$** |
|  |  | **(unaudited)** |  |
| **ASSETS** |  |  |  |
| **Current assets** |  |  |  |
| &nbsp;&nbsp;Cash |  | 201647 | 100410 |
| &nbsp;&nbsp;Restricted cash |  | 8250 | 8390 |
| &nbsp;&nbsp;Accounts receivable, net of allowance | Note 3 | 454765 | 446283 |
| &nbsp;&nbsp;Inventory  | Note 4 | 1676545 | 1669053 |
| &nbsp;&nbsp;Prepaid asset |  | 40533 | 41222 |
| &nbsp;&nbsp;Sales tax recoverable, net of allowance  | Note 5 | 96025 | 60506 |
| &nbsp;&nbsp;Other receivable | Note 8 | 3587 | 3648 |
| **Total current assets** |  | 2481352 | 2329512 |
| **Long term assets** |  |  |  |
| &nbsp;&nbsp;Fixed assets  | Note 6 | 3308543 | 3554463 |
| &nbsp;&nbsp;Goodwill | Note 7 | 255668 | 260016 |
| &nbsp;&nbsp;Operating lease right-of-use assets  | Note 9 | 30352 | 32758 |
| **Total long term assets** |  | 3594563 | 3847237 |
| **Total assets** |  | 6075915 | 6176749 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIENCY** |  |  |  |
| **Current liabilities**  |  |  |  |
| &nbsp;&nbsp;Bank overdraft |  | 506 | 506 |
| &nbsp;&nbsp;Accounts payable and accrued liabilities |  | 2926448 | 2637973 |
| &nbsp;&nbsp;Deferred revenue | Note 2 | 285540 | 197557 |
| &nbsp;&nbsp;Payable to related parties, net | Note 8 | 10423034 | 10361576 |
| &nbsp;&nbsp;Operating lease liability - Current portion  | Note 9 | 180188 | 175460 |
| &nbsp;&nbsp;Convertible promissory notes, net  | Note 10 | 480 | 480 |
| &nbsp;&nbsp;Derivative liability  | Note 10 | 8100 | 8057 |
| **Total current liabilities** |  | 13824296 | 13381609 |
| **Long term liabilities** |  |  |  |
| &nbsp;&nbsp;Operating lease liability - Non-current portion  | Note 9 | 795392 | 858088 |
| **Total long term liabilities** |  | 795392 | 858088 |
| **Total liabilities** |  | 14619688 | 14239697 |
| **Stockholders' deficiency** |  |  |  |
| &nbsp;&nbsp;Preferred stock | Note 11 | 100 | 100 |
| &nbsp;&nbsp;Common stock | Note 11 | 61703 | 61703 |
| &nbsp;&nbsp;Shares to be issued | Note 11 | 175439 | 175439 |
| &nbsp;&nbsp;Additional paid-in capital |  | 24985697 | 24985697 |
| &nbsp;&nbsp;Accumulated deficit |  | (32856882) | (32306526) |
| &nbsp;&nbsp;Accumulated comprehensive loss |  | (909830) | (979361) |
| **Total stockholders' deficiency** |  | (8543773) | (8062948) |
| **Total liabilities and stockholders' deficiency** |  | 6075915 | 6176749 |
| Contingencies and commitments | Note 13 |  |  |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.*

[**Table of Contents**](#TOC)

#### TARGET GROUP INC.

#### CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)

---

| | | | |
|:---|:---|:---|:---|
|  |  | **For the**<br>**three months ended** <br>**March 31, 2026**<br>**$** | **For the**<br>**three months ended** <br>**March 31, 2025**<br>**$** |
| **REVENUE** |  | 879442 | 1400439 |
| **COST OF GOOD SOLD** |  | (687655) | (629612) |
| **Gross profit** |  | 191787 | 770827 |
| **OPERATING EXPENSES** |  |  |  |
| &nbsp;&nbsp;Advisory and consultancy fee |  | 25260 | 53842 |
| &nbsp;&nbsp;Management services fee |  | 89951 | 152473 |
| &nbsp;&nbsp;Legal and professional fees |  | 34310 | 50185 |
| &nbsp;&nbsp;Depreciation expense |  | 229653 | 218476 |
| &nbsp;&nbsp;Operating lease expense  | Note 9 | 44855 | 49237 |
| &nbsp;&nbsp;Office and general |  | 77645 | 93040 |
| **Total operating expenses** |  | 501674 | 617253 |
| **OTHER EXPENSES (INCOME)** |  |  |  |
| &nbsp;&nbsp;Change in fair value of derivative and warrant liability |  | 43 | 10402 |
| &nbsp;&nbsp;Interest and bank charges |  | 288249 | 250766 |
| &nbsp;&nbsp;Exchange (income) loss |  | (35030) | 995 |
| &nbsp;&nbsp;Interest income |  |  | (16491) |
| (Allowance) recovery of sales tax recoverable |  | (12793) | 4426 |
| &nbsp;&nbsp;Debt issuance cost |  |  | 11689 |
| **Total other expense** |  | 240469 | 261787 |
| **Net loss before income taxes** |  | (550356) | (108213) |
| &nbsp;&nbsp;Income taxes |  |  |  |
| **Net loss** |  | (550356) | (108213) |
| &nbsp;&nbsp;Foreign currency translation adjustment |  | 69531 | (2784) |
| **Comprehensive loss** |  | (480825) | (110997) |
| loss per share - basic and diluted |  | (0.0009) | (0.0002) |
| Weighted average shares - basic and diluted |  | 617025999 | 617025999 |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.*

[**Table of Contents**](#TOC)

#### TARGET GROUP INC.
**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(UNAUDITED) FOR THE THREE MONTHS ENDED MARCH 31, 2026**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Preferred stock** | <br>**Common stock** | **Shares to be issued** | **Shares to be issued** | | | | | |
|  | **Shares**

# | **Shares**<br>$# | **Shares**<br>$# | **Amount**<br>$ | **Stock**<br>**subscription**<br>**receivable**<br>$ | **Additional**<br>**paid-in**<br>**capital**<br>$ | <br>**Accumulated**<br>**deficit**<br>$ | **Accumulated**<br>**comprehensive**<br>**loss**<br>$ | <br>**Total**<br>$ |
| **As at December 31, 2025** | 1000000 | 617025999 | 1641520 | 175439 |  | 24985697 | (32306526) | (979361) | (8062948) |
| Net loss |  |  |  |  |  |  | (550356) |  | (550356) |
| Foreign currency translation |  |  |  |  |  |  |  | 69531 | 69531 |
| **As at March 31, 2026** | 1000000 | 617025999 | 1641520 | 175439 |  | 24985697 | (32856882) | (909830) | (8543773) |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.*

[**Table of Contents**](#TOC)

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(UNAUDITED) FOR THE THREE MONTHS ENDED MARCH 31, 2025**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Preferred stock** | <br>**Common stock** | **Shares to be issued** | **Shares to be issued** | | | | | |
|  | **Shares**

# | **Shares**<br>$# | **Shares**<br>$# | **Amount**<br>$ | **Stock**<br>**subscription**<br>**receivable**<br>$ | **Additional**<br>**paid-in**<br>**capital**<br>$ | <br>**Accumulated**<br>**deficit**<br>$ | **Accumulated**<br>**comprehensive**<br>**loss**<br>$ | <br>**Total**<br>$ |
| **As at December 31, 2024** | 1000000 | 617025999 | 1641520 | 175439 |  | 24985697 | (30946844) | (783724) | (6507629) |
| Net loss |  |  |  |  |  |  | (108213) |  | (108213) |
| Foreign currency translation |  |  |  |  |  |  |  | (2784) | (2784) |
| **As at March 31, 2025** | 1000000 | 617025999 | 1641520 | 175439 |  | 24985697 | (31055057) | (786508) | (6618626) |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.*

[**Table of Contents**](#TOC)

#### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**three months ended** <br>**March 31, 2026**<br>**$** | **For the**<br>**three months ended** <br>**March 31, 2025**<br>**$** |
| **OPERATING ACTIVITIES** |  |  |
| Net loss for the period | (550356) | (108213) |
| **Adjustment for non-cash items** |  |  |
| &nbsp;&nbsp;Change in fair value of derivative and warrant liability | 43 | 10402 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Recovery) allowance of sales tax recoverable | (12793) | 4426 |
| &nbsp;&nbsp;Depreciation expense | 229653 | 218476 |
| &nbsp;&nbsp;Operating lease expense | 41799 | 45547 |
| &nbsp;&nbsp;Debt issuance cost |  | 11689 |
| ***Changes in operating assets and liabilities:*** |  |  |
| &nbsp;&nbsp;Change in accounts receivable - net of allowance | (16168) | (569388) |
| &nbsp;&nbsp;Change in inventory | (35973) | 98292 |
| &nbsp;&nbsp;Change in sales tax recoverable | (24328) | 17411 |
| &nbsp;&nbsp;Change in accounts payable and accrued liabilities | 262950 | (234525) |
| &nbsp;&nbsp;Change in operating lease liability, net | (81254) | (76896) |
| &nbsp;&nbsp;Changes in interest receivable |  | 12774 |
| &nbsp;&nbsp;Change in deferred revenue | 92762 |  |
| **Net cash (used) from operating activities** | (93665) | (570005) |
| **INVESTING ACTIVITIES** |  |  |
| Amounts invested on fixed assets | (40055) | 93 |
| Advancement on convertible note |  | 27872 |
| **Net cash (used) provided by investing activities** | (40055) | 27965 |
| **FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;Proceeds from loans from related parties | 240570 |  |
| &nbsp;&nbsp;Settlement of related party loan |  | (557440) |
| **Net cash provided (used) by financing activities** | 240570 | (557440) |
| **Net change in cash and restricted cash during the period** | 106850 | (1099480) |
| Effect of foreign currency translation | (5753) | 3424 |
| Cash and restricted cash, beginning of period | 108800 | 1877759 |
| **Cash and restricted cash, end of period** | 209897 | 781703 |
| **NON-CASH INVESTING AND FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;Shares issued as consideration for services |  |  |
| **SUPPLEMENTARY CASH FLOW INFORMATION** |  |  |
| &nbsp;&nbsp;Cash paid for interest |  | 1080040 |
| &nbsp;&nbsp;Cash paid for taxes |  |  |

---

*The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.*

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

1.&nbsp;&nbsp;&nbsp;&nbsp; Organization, Nature of Business, Going Concern and Management Plans

#### Organization and Nature of Business
Target Group Inc. ("Target Group" or the "Company") was incorporated on July 2, 2013, under the laws of the state of Delaware, to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. On July 3, 2018, the Company filed an amendment in its Certificate of Incorporation to change its name to Target Group Inc., and the Company secured the OTC Bulletin Board symbol CBDY from the Financial Industry Regulatory Authority (FINRA).

Target Group is a diversified, vertically integrated, progressive cannabis company with a focus nationally and internationally. The Company wholly owns and operates Canary Rx Inc, a Canadian licensed cannabis producer ("Canary"), regulated under The Cannabis Act (Bill C-45). Canary, operates a 44,000 square foot facility located in Norfolk County, Ontario. The Company has structured multiple international production and distribution platforms and continues to expand its global footprint, focused on building an iconic brand portfolio with cutting-edge intellectual property in both the medical and recreational cannabis markets. Target Group is committed to building industry-leading companies that transform the perception of cannabis and responsibly elevate the overall patient and consumer experience.

The Company's core business is producing, manufacturing, distributing, and selling of cannabis products. As of the current year to date period end, Canary has produced and sold cannabis products of $879,442 (Period ended March 31, 2025: $1,400,439).

*CL Investors Debt Purchase and Assignment Agreement*

On June 15, 2020, the Company, its first–tier subsidiaries Visava Inc. ("Visava") CannaKorp Inc. ("CannaKorp"), and the Company's second-tier subsidiary, Canary entered into a Debt Purchase and Assignment Agreement ("Debt Agreement") with CL Investors Inc., a corporation organized under the laws of the Province of Ontario, Canada ("CLI"). While June 15, 2023 was the preliminary date of the Debt Agreement, it was not finalized until the later date as indicated below. The CEO and director of the Company is a shareholder and the Secretary of CLI, and the brother of the CEO is the President and sole director of CLI therefore the below loan from CLI is classified under related party transactions.

Pursuant to the Debt Agreement, CLI purchased from the Company for the sum of $2,080,460 (CAD $2,900,000) a debt obligation owing from Canary to the Company in the principal balance of $7,604,440 (CAD $10,600,000 ("Canary Debt")). Upon receipt of the consideration, the Company loaned the full sum to Canary under terms of an unsecured, non-interest-bearing promissory note ("Note"), subject to a covenant by the Company not to take any collection action so long as the Canary Debt remains unpaid to CLI. As of March 31, 2026, $3,587 (CAD $5,000) is still outstanding from CLI which is presented as other receivable on the unaudited condensed consolidated interim balance sheet.

As a condition of the closing of the Debt Agreement, the terms of the Canary Debt were amended to provide for interest at 5% per annum with a maturity date of 60 months from the date of the Debt Agreement ("Term"). The Canary Debt was to be repaid according to the following schedule:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) In the first year of the Term, Canary will pay CLI the greater of $810,662 (CAD 1,130,000) and fifty percent (50%) of the Net Revenue (hereinafter defined), provided that where the latter amount exceeds the former amount, Canary will, by the end of such first year, pay CLI no less than the former amount and Canary will, within thirty (30) days following the end of such first year, pay CLI the balance of such amount owing for such first year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) In the second year of the Term, Canary will pay CLI the greater of $1,506,540 (CAD 2,100,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2021, provided that where the latter amount exceeds the former amount, Canary will, within thirty (30) days following the end of such second year, pay CLI the balance of such amount owing for such second year;

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) In the third year of the Term, Canary will pay CLI the greater of $2,310,028 (CAD 3,220,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2022, provided that where the latter amount exceeds the former amount, Canary will, by the end of such third year, pay CLI no less than the former amount and Canary will, within thirty (30) days following the end of such third year, pay CLI the balance of such payments owing for such third year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) In the fourth year of the Term, Canary will pay CLI the greater of $2,209,592 (CAD 3,080,000) and fifty percent (50%) of the Net Revenue, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2023, provided that where the latter amount exceeds the former amount, Canary will, within thirty (30) days following the end of such fourth year, pay CLI the balance of such amount owing for such fourth year; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) In the fifth year of the Term, Canary will pay CLI the balance owing under this Note, by way of twelve (12) consecutive monthly installments payable on the 14th day of each month commencing on August 14, 2024, for an amount calculated by dividing twelve (12) into the sum of all amounts owing under this Note at the beginning of the fifth year of the Term on account of Principal and Interest, provided that where further amounts are owing under this Note at the end of such fifth year, Canary will pay CLI all such further amounts within five (5) days following the end of such fifth year.

For the purpose of the Note, "Net Revenue" means any and all revenue generated from Canary's Licensed Facility (hereinafter defined) to which it is entitled to net of applicable taxes and third-party expenses.

The repayment of the Canary Debt, as amended, was guaranteed by the Company's wholly-owned subsidiaries Vivasa and CannaKorp. and secured by (i) a general security interest in the assets of the Company, Canary, Visava and CannaKorp, respectively; and (ii) a pledge by the Company of all of the issued and outstanding common stock of Canary, Visava and CannaKorp, held by the Company. In addition to the foregoing guarantees, security interest and stock pledge, CLI was granted an option, in lieu of repayment of the amended Canary Debt, to demand, in its sole and absolute discretion the transfer, assignment and conveyance of 75% of the issued and outstanding capital stock of Visava and Canary. Furthermore, the President and sole director of CLI was granted an option to acquire the remaining 25% of the issued and outstanding capital stock of Visava and Canary.

Effective August 14, 2020, the Debt Agreement was amended ("Amendment") to provide that CLI would purchase from Rubin Schindermann, a director of the Company, 500,000 shares of the Company's Series A Preferred Stock in consideration of the payment by CLI to Rubin Schindermann of $71,740 (CAD $100,000) and the issuance to Schindermann of 10,000,000 shares of the Company's common stock. In consideration of the foregoing, Mr. Schindermann resigned as a director of the Company and from any and all administrative and executive positions with the Company's subsidiaries Visava, Canary and CannaKorp, respectively. In addition, the Company issued Common Stock Purchase Warrant for 10,000,000 shares of Target Group's common stock to CLI as consideration for the Debt Agreement ("CLI Warrants"). Refer to Note 11 for additional details on the CLI Warrants. The combined impact of both transactions resulted in debt issuance cost of $251,518. This debt issuance cost will be amortized over the term of the debt on a straight-line basis.

The transactions contemplated by the Debt Agreement and the Amendment closed on August 14, 2020.

#### Going Concern
During the three months ended March 31, 2026, the company has generated revenue but has also incurred operating losses for the three months ended March 31, 2026. The Company had a working capital deficit of $11,342,944 and an accumulated deficit of $32,856,882 as of March 31, 2026. The Company's continuation as a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations and/or obtaining additional financing from its members or other sources, as may be required.

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

The unaudited accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern up to at least 12 months from the balance sheet date; however, the above condition raises substantial doubt about the Company's ability to do so. The unaudited condensed consolidated interim financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

In order to maintain its current level of operations, the Company will require additional working capital from either cash flow from operations, sale of its equity or issuance of debt. If the Company is unable to acquire additional working capital, it will be required to significantly reduce its current level of operations.

2.&nbsp;&nbsp;&nbsp;&nbsp; Summary of Significant Accounting Policies

#### Basis of Presentation and Consolidation
The unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information and the rules and regulations of the SEC and are expressed in United States Dollars ("USD"). Accordingly, the unaudited condensed consolidated interim financial statements do not include all information and footnotes required by US GAAP for complete annual financial statements. The unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the year ending December 31, 2026, or for any other interim period. The unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto as of and for the year ended December 31, 2025.

The unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Visava, Canary, CannaKorp, and JVCo. Significant intercompany accounts and transactions have been eliminated.

#### Use of Estimates
**The preparation of the unaudited condensed consolidated interim financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated interim financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to accruals. Actual results could differ from those estimates.**

**Cash**

The Company places its cash with high-quality banking institutions. The Company do not have cash balances in excess of the Federal Deposit Insurance Corporation (FDIC) limit as of March 31, 2026 and December 31, 2025.

Cash and cash equivalents include cash on hand and deposits at banking institutions as well as all highly liquid short-term investments with original maturities of 90 days or less. The Company did not have cash equivalents as of March 31, 2026 and December 31, 2025.

Restricted cash represents deposits made to the Company's bank as a requirement to use the bank's credit card which is not available for immediate or general business use.

**Fixed Assets**

Fixed assets are reported at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets, commencing when the assets become available for productive use, based on the following estimated useful lives:

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

Depreciation is calculated using the following terms and methods:

---

| | | |
|:---|:---|:---|
| Furniture & office equipment | Straight-line | 7 years |
| Machinery & equipment | Straight-line | 3-5 years |
| Software  | Straight-line | 3 years |
| Leasehold improvements | Straight-line | Lease period |

---

An item of equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising from the derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the profit or loss in the period the asset is derecognized. The assets' residual values, useful lives and methods of depreciation are reviewed at each reporting date, and adjusted prospectively, if appropriate.

**Shipping and Handling Cost**

Payments by customers to us for shipping and handling costs are included in revenue on the consolidated statements of operations, while our expense is included in cost of goods sold. Shipping and handling for inventory, if any, are included as a component of inventory on the consolidated balance sheets, and in cost of goods sold in the consolidated statements of operations when the product is sold.

**Fair Value of Financial Instruments**

The Company follows guidance for accounting for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the unaudited condensed consolidated interim financial statements on a recurring basis. Additionally, the Company adopted guidance for fair value measurement related to nonfinancial items that are recognized and disclosed at fair value in the unaudited condensed consolidated interim financial statements on a nonrecurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy are as follows:

● Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

● Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

● Level 3 inputs are unobservable inputs for the asset or liability. The carrying amounts of financial assets such as cash approximate their fair values because of the short maturity of these instruments.

**The estimated fair value of cash and accounts payable and accrued liabilities approximate their carrying values due to the short-term maturity of these instruments. The derivative liabilities of the promissory convertible notes and warrant liabilities are valued Level 3. Refer to Note 10 for further details.**

#### Revenue recognition
The Company adopted ASC 606 effective January 1, 2019, using the modified retrospective method after electing to delay the adoption of the accounting standard as the Company qualified as an "emerging growth company". Since the Company did not have any contracts as of the effective day, therefore, there was no material impact on the consolidated financial statements upon adoption of the new standard. Revenue is recognized when performance obligations under the terms of the contracts with our customers are satisfied. Our performance obligation generally consists of the promise to sell our finished products to our customers, wholesalers, distributors or retailers. Control of the finished products is transferred upon shipment to, or receipt at, our customers' locations, as determined by the specific terms of the contract. Once control is transferred to the customer, we have completed our performance obligation, and revenue is recognized.

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

The Company generated revenue of $879,442 during the three months ended March 31, 2026 whereas $1,400,439 in March 31, 2025.

The Company revenue was to four customers (March 31, 2025: eleven customers). The revenue represents the sale of cannabis products. Since the customers have received the product and there are no further obligations as per the agreement, revenue was recognized.

Deferred revenue represents amounts received by the company for which the related goods have not yet been delivered or performed.

#### Segment Reporting
The Company operates as a single operating segment in accordance with FASB ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. All financial information is presented on a consolidated basis and reviewed by Chief Executive Officer as the Chief Operating Decision Maker (CODM). The CODM uses consolidated net loss, as presented in the consolidated statement of operations, to assess segment performance and allocate resources.

The following table presents the Company's revenue by geographic region:

---

| | |
|:---|:---|
| Germany | $507017 |
| Portugal | $225388 |
| Australia | $115185 |
| Canada | $31852 |
|  | $879442 |

---

The Company's net (loss) income for the year ended is summarized in the table below.

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**three months ended**<br>**March 31, 2026**<br>**$** | **For the**<br>**three months ended**<br>**March 31, 2025**<br>**$** |
| **Net loss** | (550356) | (108213) |

---

**3.**&nbsp;&nbsp;&nbsp;&nbsp; **Accounts Receivables**

Accounts receivable are recorded at the net value of the face amount less an allowance for doubtful accounts. As of March 31, 2026, the company's allowance for doubtful accounts was $2,715 (2025: $2,632).

4.&nbsp;&nbsp;&nbsp;&nbsp; Inventory

As of March 31, 2026, the inventory in the amount of $1,676,545 (2025: $1,669,053) consists of work-in-progress and finished cannabis goods.

---

| | |
|:---|:---|
| **Product** | **As at**<br>**March 31, 2026** |
|  | $|
| Finished goods | 1226964 |
| WIP (Flowers and plants) | 449581 |
|  | 1676545 |

---

5.&nbsp;&nbsp;&nbsp;&nbsp; Sales Tax Recoverable and Payable

As of March 31, 2026, the Company had $115,252 of gross sales tax recoverable compared to December 31, 2025 there was $67,256, while the Company had $nil of gross sales tax payable as of March 31, 2026.

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

Recoverable is due to the sales tax paid by the Company on expenses incurred during the year which are recoverable from the government while payable is due to the sales tax received (after deducting sales tax paid on expenses incurred by the Company) during the year which are payable from the government due to sales conducted through the Joint Venture.

The Company has recorded $19,227 (December 31, 2025: $6,750) of allowance as of March 31, 2026.

6.&nbsp;&nbsp;&nbsp;&nbsp; Fixed Assets

The Company's subsidiary, Canary, initiated construction on its leased 44,000 square foot cannabis cultivation facility in September of 2017. Since then, extensive demolition and structural upgrades have been carried out at the site. On May 1, 2019, the Company completed the construction of its 44,000 square foot cannabis cultivation facility and on May 14, 2019, the Company submitted a Site Evidence Package to Health Canada as part of the steps to obtain the license to cultivate cannabis at the Company's facility. On October 8, 2019, the Company was granted licenses to cultivate, process and sell cannabis pursuant to the Cannabis Act (Bill C-45). Canary currently operates as a licensed producer/wholesaler of craft cannabis in Ontario and has since been granted its sales amendment from Health Canada to sell directly to provincial retail boards for consumer products.

Canary has recorded a depreciation expense of $206,905 during the three months ended March 31, 2026 (March 31, 2025: $196,733) while CannaKorp has recorded a depreciation expense of $nil during the three months ended March 31, 2026 (March 31, 2025: $nil). Target recorded a depreciation of $98 during the three months ended March 31, 2026 (March 31, 2025: $93). JVCo recorded depreciation of $22,650 during the three months ended March 31, 2026 (March 31, 2025: $21,650).

Below is a breakdown of the consolidated fixed asset, category wise:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Furniture &** <br>**fixture**<br>**$** | **Machinery &**<br>**Equipment**<br>**$** | <br>**Software**<br>**$** | **Leasehold**<br>**improvements**<br>**$** | <br>**Total**<br>**$** |
| Cost | 1411311 | 768589 | 51559 | 6676462 | **8907921** |
| Accumulated depreciation | (977380) | (767966) | (48220) | (3805812) | **(5599378)** |
|  | **433931** | **623** | **3339** | **2870650** | **3308543** |

---

7.&nbsp;&nbsp;&nbsp;&nbsp; Goodwill

#### Business Acquisition
ASC Topic 805, "Business Combinations" requires that all business combinations be accounted for using the acquisition method and that certain identifiable intangible assets acquired in a business combination be recognized as assets apart from goodwill. ASC Topic 350, "Intangibles-Goodwill and Other" ("ASC 350") requires goodwill and other identifiable intangible assets with indefinite useful lives not be amortized, such as trade names, but instead tested at least annually for impairment (which the Company tests each year end, absent any impairment indicators) and be written down if impaired. ASC 350 requires that goodwill be allocated to its respective reporting unit and that identifiable intangible assets with finite lives be amortized over their useful lives.

#### Visava/Canary
On June 27, 2018, the Company entered into an Agreement and Plan of Share Exchange ("Exchange Agreement") with Visava, then a private Ontario, Canada corporation. Visava owns 100% of Canary.

Pursuant to the Agreement, the Company acquired 100% of the issued and outstanding shares of Visava in exchange for the issuance of 25,500,000 shares of the Company's Common Stock and issued to the Visava shareholders, prorata Common Stock Purchase Warrants ("Visava Warrants") purchasing an aggregate of 25,000,000 shares of the Company's Common Stock at a price per share of $0.10 for a period of two years following the issuance date of the Visava Warrants. As a result of this transaction, Visava became a wholly-owned subsidiary of the Company and the former shareholders of Visava owned approximately 46.27% of the Company's shares of Common Stock. The transaction was closed effective August 2, 2018. During the year ended, December 31, 2020, all of the Visava Warrants expired, none were exercised.

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

This acquisition was accounted for using the acquisition method of accounting. As of August 2, 2018, the fair value of the net liabilities was $275,353 and the purchase consideration was fair valued as $3,318,842, shown below, leading to a goodwill allocation of $3,594,195.

---

| | |
|:---|:---|
|  | **$** |
| Number of Common Stock | 25500000 |
| Market price on the date of issuance | 0.067 |
| **Fair value of Common Stock** | **1695750** |

---

---

| | |
|:---|:---|
|  | **$** |
| Number of warrants | 25000000 |
| Fair value price per warrant | 0.065 |
| **Fair value of warrant** | **1623092** |
| Fair value of Common Stock | 1695750 |
| Fair value of warrant | 1623092 |
| **Purchase consideration** | **3318842** |

---

The fair value of these warrants was measured at the date of acquisition using the Black-Scholes option pricing model using the following assumptions:

● Forfeiture rate of 0% ;

● Stock price of $0.067 per share;

● Exercise price of $0.10 per share

● Volatility at 329%

● Risk free interest rate of 2.66% ;

● Expected life of 2 years; and

● Expected dividend rate of 0%

During the year ended December 31, 2025, the Company has identified no circumstances which would call for further evaluation of goodwill impairment related to Canary (December 31, 2024 the Company has identified no circumstances which would call for further evaluation of goodwill impairment related to Canary).

During the quarter ended, March 31, 2026, all of the Visava Warrants expired, none were exercised.

#### Goodwill
The Company tests for impairment of goodwill at the reporting unit level. In assessing whether goodwill is impaired, the Company utilizes the two-step process as prescribed by ASC 350. The first step of this test compares the fair value of the reporting unit, determined based upon discounted estimated future cash flows, to the carrying amount, including goodwill. If the fair value exceeds the carrying amount, no further work is required and no impairment loss is recognized. If the carrying amount of the reporting unit exceeds the fair value, the goodwill of the reporting unit is potentially impaired and step two of the goodwill impairment test would need to be performed to measure the amount of an impairment loss, if any. In the second step, the impairment is computed by comparing the implied fair value of the reporting unit's goodwill with the carrying amount of the goodwill. If the carrying amount of the reporting unit's goodwill is greater than the implied fair value of its goodwill, an impairment loss in the amount of the excess is recognized and charged to the statement of operations.

8.&nbsp;&nbsp;&nbsp;&nbsp; Related Party Transactions and Balances

During the three months ended March 31, 2026, the Company expensed $89,951 (March 31, 2025: $152,473) in management service fee for services provided by the current key officers of the company.

The breakdown of the related party balance as of March 31, 2026 of $10,432,034 (December 31, 2025: $10,361,576) is below:

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

*Debt purchase by CL Investors Inc.*

On June 15, 2020, the Company and its subsidiaries, entered into a Debt Agreement with CLI explained in Note 1. The Canary Debt, Term, repayment schedule, security and options are set forth in Note 1.As of March 31, 2026, $3,587 (CAD $5,000) is still outstanding from CLI.

Interest expense charged for the three months ended in the amount of $94,976 (CAD $130,282) is included in interest and bank charges on the unaudited condensed consolidated interim statement of operations and comprehensive loss and accrued interest in the amount of $904,411 (CAD 1,260,679) is included in accounts payable and accrued liabilities on the unaudited condensed consolidated interim balance sheet.

The repayment schedule of the minimum principal payments is shown below:

---

| | |
|:---|:---|
| 2027 | $7477121 |
| Total | 7477121 |
| Current portion | (7477121) |
| Non-current portion | $— |

---

During the period ended March 31, 2026, the Company made no payments to the CLI loan.

The Company has reclassified the entire outstanding balance of the loan to current liabilities. At this stage the Company is under discussions to formalize the arrangements with the lender to revise the terms of the loans.

The Debt Agreement Amendment and CLI Warrants are explained in Note 1. Refer to Note 11 for additional details on the CLI Warrants. The combined impact of both transactions resulted in a debt issuance cost of $251,518. This debt issuance cost will be amortized over the term of the debt on a straight-line basis. As at March 31, 2026, the balance is $nil.

*Shareholder loan*

One of the Company's shareholders provided a loan to the Company. The loan is secured by all assets owned by the Company and its subsidiaries including leasehold improvements and matures on August 31, 2026 and therefore is presented as non-current. The loan was provided in six tranches and the latest amendment increased the maximum loan amount by $626,040 (CAD 900,000) while the rest of terms remained unchanged. The specific details of each tranche of the loan are shown below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Interest rate** | **Maximum loan** | **Maximum loan** | **Outstanding loan** | **Outstanding loan** |
|  |  | **CAD** | **USD** | **CAD** | **USD** |
| Tranche 1  | 16.00% | 1043593 | 748674 | 1043593 | 748674 |
| Tranche 2 | 43.26% | 1592787 | 1142665 | 1592787 | 1142665 |
| Tranche 3 | 43.26% | 150000 | 107610 | 150000 | 107610 |
| Tranche 4 | 43.26% |  |  |  |  |
| Tranche 5 | 43.26% | 100000 | 71740 |  |  |
| Tranche 6 | 43.26% | 330000 | 236742 | 330000 | 236742 |
| Total |  | 3216380 | 2307431 | 3116380 | 2235691 |

---

Interest expense charged for the three months ended March 31, 2026 in the amount of $191,197 (CAD $262,273) is included in interest and bank charges on the unaudited condensed consolidated interim statement of operations and comprehensive loss and accrued interest in the amount of $521,198 (CAD 726,510) is included in accounts payable and accrued liabilities on the unaudited condensed consolidated balance sheet.

The Eleventh Amending Agreement to the shareholder loan, was executed on August 11, 2025, by and between Jerry Zarcone (the "Lender"), the Company and its subsidiaries ("Eleventh Amendment"), which extended the term of each of the First, Second, Third, Fourth, and Fifth Tranche, to a maturity date of August 31, 2026, or such earlier date as demanded by Mr. Zarcone. Effective January 25, 2026, the Company and Lender entered into a Twelfth Amending Agreement pursuant to which Lender advanced the Company an

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

additional CDN$330,000.00 (the "*Sixth Tranche*") under the shareholder loan. The Sixth Tranche carries interest at the rate of 3.0416% per month (43.26% per annum) and is subject to a Lender's fee of CDN$33,000.00 which was deducted and paid from the Sixth Tranche. The maturity date of the Sixth Tranche is December 31, 2026. At Company's request, and Lender's sole option, Lender may advance up to an additional CDN$500,000.00, subject to a Lender's fee of ten percent (10%) of the amount of the additional advance, bearing the same interest rate and maturity date as the Sixth Tranche.

*Outstanding management service fee*

The balance owing to key officers of the Company is $645,055 (December 31, 2025: $659,189).

*Balances outstanding related to subsidiaries*

During the year ended December 31, 2019, the Company settled with the loan holders provided to the Company's subsidiary, CannaKorp. The total amount subject to settlement was $817,876 which includes accrued interest and accrued payroll. The company settled by paying $954,374 as consideration of cash, 920,240 shares (recorded in shares to be issued) and warrants of 920,240 shares with an exercise price of $0.15 per share. This resulted in a settlement loss of $136,498. These warrants expired during the year ended December 31, 2021. Of the total settlement amount, as of March 31, 2026 and December 31, 2025, $65,000 was outstanding to be paid. This amount includes late payment penalties of $25,000. During the period ended March 31, 2026, all of the warrants expired, none were exercised.

*Balances outstanding related to directors*

During the three months ended March 31, 2026, the Company has purchased $nil of consulting services from GTA Angel Group which is owned by the Company's CEO's brother. The balance outstanding as of March 31, 2026 is $24,320 and is included in accounts payable and accrued liabilities.

The Company subleases its principal executive office premise from Norlandam Marketing Inc., a company owned by one of the directors. During the quarter ended March 31, 2021, the premises were subleased to a third party that makes rent payments directly to Norlandam Marketing Inc. The balance outstanding as of March 31, 2026 and December 31, 2025 is $nil.

**9.&nbsp;&nbsp;&nbsp;&nbsp; Operating Lease Right-Of-Use Assets and Lease Liability**

The Company adopted ASC 842 as of January 1, 2019, using a modified retrospective approach and applying the standard's transition provisions at January 1, 2020, the effective date. The Company made an accounting policy election to exclude from balance sheet reporting those leases with initial terms of 12 months or less. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components is recognized when the obligation is probable.

Right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company's leases, the incremental borrowing rate is used based on the information available at the adoption date in determining the present value of lease payments. The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.

The Company does not own any real property. It currently leases two office/facility spaces. For accounting purposes, this lease is treated as an operating leases. Upon adoption of ASC 842, the Company recognized $1,620,041 (CAD $2,258,212) of right-to-use assets as

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

operating leases and operating lease obligations. The right-to-use asset was reduced by $1,499,309 (CAD $2,089,921) due to recognition of the prior deferred rent liability which was eliminated upon adoption of ASC 842. Details of these leases are detailed below:

During the quarter ended March 31, 2021, the Company subleased its executive premises to a third party that makes rent payments directly to the landlord. However, if the sub-lessee cancels its sub-lease agreement with the landlord during the Company's lease term with the landlord (ended on August 30, 2023), the Company will be responsible for making rent payments for the period from the date of cancellation by the sub-lessee to August 30, 2023. This sub-lease has matured and not been renewed.

The Company's second-tier subsidiary, Canary, is a party to a 10-year lease agreement (initiated in July 2014) with respect to its facility to produce craft cannabis at scale. The lease agreement was amended effective January 1, 2020, where the amended 10-year term starts on May 1, 2020 and provides the Company with an option to extend for three (3) additional terms of ten (10) years. Additionally, effective January 1, 2020, the amended agreement increased the minimum rent to $25,109 (CAD $35,000) plus applicable taxes per month and on each anniversary date, commencing from January 1, 2021, the minimum rent will increase by 1.00%. Furthermore, only the current 10-year term has been factored into the calculation of the lease liability. Effective May 1, 2020, due to the implementation of the new lease, $709,001 (CAD $988,293) was forgiven by the landlord and one vendor.

These leases will expire between 2026 and 2030. The weighted average discount rate used for these leases was 16% (average borrowing rate of the Company). Maturities of lease liabilities were:

---

| | |
|:---|:---|
| 2026 | $239883 |
| 2027 | 323043 |
| 2028 | 326273 |
| 2029 | 329536 |
| Thereafter | 110945 |
| Total lease payments | 1329680 |
| Less imputed interest | (354100) |
| Present value of lease liabilities | 975580 |
| Current portion | (180188) |
| Non-current portion | $795392 |

---

Below is the reconciliation of the net operating lease presented on the unaudited condensed consolidated interim statement of operations:

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**three months ended** <br>**March 31, 2026** | **For the**<br>**three months ended** <br>**March 31, 2025** |
|  | **$** | **$** |
| Gross operating lease expense | 41799 | 45547 |
| Gross rent and utilities expenses | 3056 | 3690 |
|  | 44855 | 49237 |

---

10. Convertible Promissory Notes

Interest amounting to $9 was accrued for the three months ended March 31, 2026 (March 31, 2025: $9).

Principal amount outstanding as of March 31, 2026 and December 31, 2025 was $480. At both reporting dates, the entire balance was current.

All notes maturing prior to the date of this report are outstanding.

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

*Derivative liability*

During the three months ended March 31, 2026, there were no conversion of principal balance of convertible promissory notes (March 31, 2025: $nil). The Company recorded and fair valued the derivative liability as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Derivative**<br>**liability as at**<br>**December 31,** <br>**2025** | **Conversions /**<br>**Redemption**<br>**during the**<br>**period** | <br>**Change due to**<br>**Issuances** | <br>**Fair value**<br>**adjustment** | **Derivative**<br>**liability as at**<br>**March 31,** <br>**2026** |
|  | **$** | **$** | **$** | **$** | **$** |
| Note D | 902 |  |  | 12 | 914 |
| Note F | 5248 |  |  | 23 | 5271 |
| Note G | 1907 |  |  | 8 | 1915 |
|  | **8057** | **—** | **—** | **43** | **8100** |

---

#### Key assumptions used for the valuation of convertible notes
Derivative element of the convertible notes was fair valued using a multinomial lattice model. Following assumptions were used to fair value these notes as of March 31, 2026:

● Projected annual volatility of 157% to 157% ;

● Risk free interest rate of 3.69% to 3.69% ;

● Stock price of $0.002 ;

● Liquidity term of 0.25 years;

● Dividend yield of 0% ; and

● Exercise price of $0.0018 to $0.0151 .

11. Stockholders' Equity

#### Capitalization
*Preferred Stock*

● Par value: $0.0001

● Authorized: 20,000,000

● Issued: 1,000,000 shares were outstanding as of March 31, 2026 and December 31, 2025

*Common Stock*

● Par value: $0.0001

● Authorized: 850,000,000

● Issued: 617,025,999 shares are outstanding as at March 31, 2026 and December 31, 2025

As of March 31, 2026, convertible notes and preferred stock outstanding could be converted into 40,328,827 (December 31, 2025: 36,361,915) and 100,000,000 (December 31, 2025: 100,000,000) shares of common stock, respectively.

#### Preferred Stock
**Shares of preferred stock may be issued from time to time in one or more series as may be determined by the board of directors. The board of directors may fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof without any further vote or action by the stockholders of the Company, except that no holder of preferred stock shall have pre-emptive rights. Any shares of preferred stock so issued would typically have priority over the common stock concerning dividend or liquidation rights. The board of directors does not at present intend to seek stockholder approval prior to any issuance of currently authorized stock unless otherwise required by law.**

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

#### Series A Preferred Stock ("Series A Stock")
**Dividends shall be declared and set aside for any shares of Series A Stock in the same manner and amount as for the Common Stock. Series A Stock, as a class, shall have voting rights equal to a multiple of 2X the number of shares of Common Stock issued and outstanding that are entitled to vote on any matter requiring shareholder approval. The Series A Stockholders shall not vote as a separate class but shall vote together with the common stock on all matters, including any amendment to increase or decrease the authorized capital stock. Upon the voluntary or involuntary dissolution, liquidation or winding up of the corporation, the assets of the Company available for distribution to its shareholders shall be distributed to the holders of common stock and the holders of the Series A Stock ratable without any preference to the holders of the Series A Stock. Shares of Series A Stock can be converted at any time into fully paid and nonassessable shares of Common Stock at the rate of one hundred (100) shares of Common Stock for each one (1) share of Series A Stock.**

#### Common Stock
Holders of shares of common stock are entitled to one vote for each share on all matters to be voted on by the stockholders. Holders of common stock do not have cumulative voting rights.

Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to share ratable in dividends, if any, as may be declared from time to time by the board of directors in its discretion from funds legally available therefore.

Holders of common stock have no pre-emptive rights to purchase the Company's common stock. There are no conversion or redemption rights or sinking fund provisions with respect to the common stock. The Company may issue additional shares of common stock which could dilute its current shareholder's share value.

#### Shares to be issued include the following:
Disclosure for shares to be issued:

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares** | **Amount** | **Description** |
|  |  |  | 80,000 shares of common stock to be issued as compensation to advisers and consultants. These were recorded at fair value of $52,000, based on the market price of the Company's stock on the date of issue. |
| Services | 115000 | $73000 | 35,000 to be issued as settlement of the amount due for website development services amounting to $247,306. The fair value of the shares on the date of settlement was $21,000, resulting in a gain on settlement amounting to $226,306 during the year ended December 31, 2017. |
| Private placements | 346296 | $18787 | Consideration for private placements with the fair value based on cash proceeds received. Proper allocation between common stock and additional paid-in capital of the amount received will be completed in the period when the shares are issued. |
| Settlement of loans of CannaKorp | 930240 | $80838 | Refer to Note 8 for details. |
| Agreement with Serious Seeds | 249984 | $2814 | As consideration for intellectual property rights granted by Smit. The fair value is based on the market price of the Company's stock on the date of issue as per the agreement. |
|  | 1641520 | $175439 |  |

---

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

#### Warrants
The warrants (with an exercise price in United States Dollar) were re-classified as a liability as of December 31, 2019, and therefore have been revalued on each quarter end. The fair value of the warrants was measured on reporting dates using the Black-Scholes option pricing model using the following assumptions:

*2026*

As of the period end March 31, 2026, there were no warrants outstanding, as all previously issued warrants had expired.

*2025*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at**<br>**December 31,** <br>**2025** | **As at**<br>**September 30,** <br>**2025** | **As at**<br>**June 30,** <br>**2025** | **As at**<br>**March 31,** <br>**2025** |
| Forfeiture rate | 0% | 0% | 0% | 0% |
| Stock price | $0.002  | $0.002  | $0.002  | $0.002  |
| Exercise price | $0.350  | $0.350  | $0.350  | $0.350  |
| Volatility | 358% | 358% | 358% | 358% |
| Risk free interest rate | 3.59% | 3.83% | 3.96% | 4.03% |
| Expected life (years) | 0.05 to 0.68 | 0.01 to 1.93 | 0.01 to 1.18 | 0.01 to 1.43 |
| Expected dividend rate | 0% | 0% | 0% | 0% |

---

The fair value of the warrants issued during the year was measured at the date of acquisition using the Black-Scholes option pricing model using the following assumptions:

*2026*

As of the period end March 31, 2026, no warrants had been issued.

*2025*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **During quarter**<br>**ended**<br>**December 31, 2025** | **During quarter**<br>**ended**<br>**September 30, 2025** | **During quarter**<br>**ended**<br>**June 30, 2025** | **During quarter**<br>**ended**<br>**March 31, 2025** |
| Forfeiture rate | 0% | 0% | 0% | 0% |
| Stock price | $0.002 to $0.003 | $0.002 to $0.003 | $0.002 to $0.003 | $0.002 to $0.003 |
| Exercise price | $0.350  | $0.350  | $0.350  | $0.350  |
| Volatility | 476% | 476% | 476% | 476% |
| Risk free interest rate | 4.10% to 4.98% | 4.10% to 4.98% | 3.66% to 4.60% | 3.66% to 4.60% |
| Expected life (years) | 2 | 2 | 2 | 2 |
| Expected dividend rate | 0% | 0% | 0% | 0% |
| Fair value of warrants | $0  | $0  | $0  | $0  |

---

As of the period end March 31, 2026, no warrants were outstanding.

12. Earnings (Loss) Per Share

FASB ASC 260, Earnings Per Share provides for calculations of "basic" and "diluted" earnings per share. Basic earnings per share include no dilution and is computed by dividing net income (loss) available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings per share. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

[**Table of Contents**](#TOC)

**TARGET GROUP INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

13. Contingencies

#### Contingencies
**During the year ended December 31, 2019, a terminated employee of Canary has filed a lawsuit against the Company amounting to approximately $1,506,540 (alleged damages of CAD 2,100,000) in Ontario, Canada. Currently, the Company is defending its position and believes that the ultimate decision will be in favor of the Company. Due to the uncertainty of timing and the amount of estimated future cash flows, if any, relating to this claim, no provision has been recognized.**

A complaint for damages of $150,000 was lodged against CannaKorp by the former Chief Financial Officer of CannaKorp for outstanding professional fees. No claim has been registered. The management is of the view that no material losses will arise in respect of the legal claim at the date of these unaudited condensed consolidated financial statements. As of March 31, 2026, $188,865 has been recorded in CannaKorp's payable based on past accruals and outstanding invoices. Due to the uncertainty of timing and the amount of estimated future cash flows, if any, relating to this claim, no further amount has been recognized.

During the year ended December 31, 2020, a claim for damages of approximately $93,820 (alleged damages of CAD $130,778) was lodged against Canary by a vendor for breach of contract. The management is of the view that no material losses will arise in respect of the legal claim at the date of these unaudited condensed consolidated interim financial statements. As of March 31, 2026, $99,109 (CAD $138,150) has been recorded in the Canary's payable based on past accruals. Due to the uncertainty of timing and the amount of estimated future cash flows, if any, relating to this claim, no further amount has been recognized.

14. Subsequent Events

The Company's management has evaluated subsequent events through the date the unaudited condensed consolidated interim financial statements were issued, pursuant to the requirements of ASC 855 and has none of the subsequent events to report.

[**Table of Contents**](#TOC)

#### ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
*The information and financial data discussed below is derived from the unaudited condensed consolidated interim financial statements of the Target Group Inc. ("we," "us" or the "Company") for the three months ended March 31, 2026 and were prepared and presented in accordance with generally accepted accounting principles in the United States.*

#### Forward Looking Statements
Some of the statements contained in this Quarterly Report on Form 10-Q that are not historical facts are "forward-looking statements" which can be identified by the use of terminology such as "estimates," "projects," "plans," "believes," "expects," "anticipates," "intends," or the negative or other variations, or by discussions of strategy that involve risks and uncertainties. We urge you to be cautious of the forward-looking statements, that such statements, which are contained in this Quarterly Report, reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors affecting our operations, market growth, services, products and licenses. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of the risks we face, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, our performance or achievements to differ materially from those contemplated by such forward-looking statements include without limitation:

● Our ability to raise capital when needed and on acceptable terms and conditions;

● Our ability to attract and retain management;

● Our ability to enter into long-term supply agreements for the mineralized material;

● General economic conditions; and

● Other factors are discussed in Risk Factors herein, or on the Company's Annual Report on Form 10-K

All forward-looking statements made in connection with this Quarterly Report are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.

#### Overview
Target Group Inc. ("Target Group" or the "Company") was incorporated in the State of Delaware on July 2, 2013, under our original name of River Run Acquisition Corporation. Effective May 13, 2014, the Company changed its name to Chess Supersite Corporation. On July 3, 2018, the Company filed an amendment in its Certificate of Incorporation to change its name to Target Group Inc.

Effective July 1, 2025, the Company's common stock is quoted on the Pink Limited Market operated by OTC Markets Group Inc, under the symbol "CBDY".

#### Business and Plan of Operations

#### Cannabis Business-Canada
The Company is engaged in the cultivation, processing and distribution of curated cannabis products for the medical and adult-use recreational cannabis market in Canada and, where legalized by state legislation, in the United States. The Company sees a shift in the public's perception of cannabis from a state of prohibition to a state of legalization. In October 2018, Canada became the first major industrialized nation to legalize adult-use cannabis at the national federal level. Cannabis is still heavily regulated, however, the medical use of cannabis is now permitted in up to 29 countries and many more countries have reformed, or are considering reforming, their cannabis uses laws to include the medical and/or recreational use of cannabis.

In the 2016 publication by Deloitte, Insights and Opportunities Recreational Marijuana, the project size of the Canadian adult-use market ranged from CDN$4.9 billion to CDN$8.7 billion annually. In the 2018 publication by Deloitte, A Society in Transition, an Industry Ready to Boom, the projected size of the Canadian adult-use market in 2019 ranged from CDN$1.8 billion to CDN$4.3 billion. According to a 2025 report published by the Ontario Cannabis Store (OCS) in collaboration with Deloitte Canada, the Canadian legal cannabis industry generated CDN$28.7 billion in cumulative nationwide sales from October 2018 through 2024, primarily driven by recreational products. The Canadian medical cannabis industry experienced substantial growth since 2014.

[**Table of Contents**](#TOC)

To the Company is positioning itself with a core emphasis on wholesale and co-packaging services to accommodate all consumer-packaged goods intended for the sophisticated cannabis market and consumer in Canada and internationally. This strategy integrate cannabinoid research, analytical testing, product development and manufacturing.

Target Group's product manufacturing will include, but will not be limited to the following:

● Cannabis flower pods for vaporizer use

● Cannabis extract pods for vaporizer use

● Cannabis pre-rolls

● K-Cup infused coffee and tea pods

● Infused cannabis beverages

● Infused cannabis edibles

● Infused topical products and CBD wellness products.

**As of the date of this report, the Company and its subsidiaries do not have any operations, employees or corporate offices based in United States.**

#### Agreements
*CL Investors Debt Purchase and Assignment Agreement*

On June 15, 2020, the Company and its subsidiaries entered into the Debt Agreement with CLI explained in Note 1. The Canary Debt, Term, repayment schedule, security and options are set forth in Note 1.

As of March 31, 2026, $3,587 (CAD $5,000) is still outstanding from CLI which is presented as other receivable on the consolidated balance sheet.

The Debt Agreement Amendment and CLI Warrants are explained in Note 1. Refer to Note 11 for additional details on the CLI Warrants. The combined impact of both transactions resulted in a debt issuance cost of $251,518. This debt issuance cost will be amortized over the term of the debt on a straight-line basis.

The transactions contemplated by the Debt Agreement and the Amendment closed on August 14, 2020.

*Forward Looking Relating to Future Operations of the Company.*

Currently, the Company and its senior management are is exploring several new, additional opportunities at its Simcoe, Ontario cultivation facility to expand the Company's product offerings in other cannabis-related consumer packaged goods ("CPG") product categories.

**Employees**

As of March 31, 2026, the Company had 42 employees which include Anthony Zarcone, Chief Executive Officer.

The Company has contracted several independent contractors and consultants to provide a range of information technology and marketing services who do not receive cash compensation but receive shares of our common stock as compensation. This mitigates any need for full or part-time employees for these services.

#### Intellectual Property Protection
Company subsidiary CannaKorp, holds the following patents:

International Patent Application No. PCT/US20115/013778

Title: METHODS AND APPARATUS FOR PRODUCING HERBAL VAPO

Filing Date: January 30, 2015

[**Table of Contents**](#TOC)

Ref. No.: B1411.70000WO00

U.S. Provisional Application No.: 61/934.255

Title: CONTAINER POD AND DELIVERY SYSTEM

Filing Date: January 31, 2014

Ref. No.: B1411.70000US00

In addition, CannaKorp has proprietary rights to certain trade names, trademarks and service marks which include WISP POD<sup>TM</sup>; cPOD<sup>TM</sup>; CANNACUP<sup>TM</sup>; and WISP<sup>TM</sup>. CannaKorp also has certain proprietary formulas and processes involving herbal formulas and flavors, proprietary herbal production processes and an herbal base developed to suspend active ingredients for optimal vaporization.

At present, CannaKorp has failed to meet its annuities payments as well as maintenance fees on the 2 referenced patents. Although there has been a lapse and these patents remain unmaintained, there remains the possibility of CannaKorp reinstating these patents if done so in a reasonable amount of time. At this time, management is determining the value maintaining these patents will provide the Company. Once management has completed their assessment, the Company will proceed accordingly and advance in that determined direction moving forward. Additionally, CannaKorp is actively seeking a joint venture partner and/ or a licensor to assist in both marketing and launching the Wisp Vaporizer and Wisp Pods in both the US and Canadian legal cannabis or hemp markets.

#### Results of Operations
The Company has not generated significant revenue to date and consequently, its operations are subject to all of the risks inherent in the establishment of a new business enterprise. Analysis on the performance of the Company is as follows:

***Balance sheet – As of March 31, 2026 and December 31, 2025***

#### Cash and Restricted Cash
On March 31, 2026, the Company had cash of $201,647 (excluding restricted cash of $8,250) compared to $100,410 (excluding restricted cash of $8,390) as of December 31, 2025. The decrease is due to the loan repayments made by the company.

The change in restricted cash is due to foreign exchange conversion of balances in Canadian Dollars into United States Dollars.

**Accounts Receivable**

Accounts receivable are recorded at the net value of the face amount less an allowance for doubtful accounts. As of March 31, 2026 accounts receivable totaled $454,765 (2025: $446,283). The majority of the balance at period end is current and will be received subsequent to period end.

As of March 31, 2026, the company's allowance for doubtful accounts was $2,715 compared to $2,761 at December 31, 2025.

**Inventory**

As of March 31, 2026, the inventory in the amount of $1,676,545 (2025: $1,669,053) consists of WIP and finished cannabis goods.

---

| | |
|:---|:---|
|  | **As at** |
| **Product** | **March 31, 2026** |
|  | **$** |
| Finished goods | 1226964 |
| WIP (Flowers and plants) | 449581 |
|  | 1676545 |

---

#### Prepaid asset
On March 31, 2026, the Company had prepaid asset of $40,533 compared to $41,222 as of December 31, 2025. The balance represents the security deposit for the leased land for the facility to produce medical marijuana.

[**Table of Contents**](#TOC)

#### Sales tax recoverable and payable
On March 31, 2026 the gross sales tax recoverable is $115,252 compared to December 31, 2025 $67,256 while the gross sales tax payable as of March 31, 2026 is $nil compared to $nil as at December 31, 2025.

Recoverable is due to the sales tax paid by the Company on expenses incurred during the year which are recoverable from the government while payable is due to the sales tax received (after deducting sales tax paid on expenses incurred by the Company) during the year which are payable from the government due to sales conducted by the Joint Venture.

Sales tax recoverable allowance on March 31, 2026 is $19,227 (December 31, 2025: $6,750).

#### Goodwill
Goodwill represents the excess of the cost of an acquisition over the fair value of the Company's share of the net identifiable assets of our subsidiaries at the date of acquisition.

#### Fixed assets
The Company initiated construction on its 44,000 square foot cannabis cultivation facility in September of 2017. On May 1, 2019, the Company completed the construction of its 44,000 square foot cannabis cultivation facility and on May 14, 2019, the Company submitted a Site Evidence Package to Health Canada as part of the steps to obtain the license to cultivate cannabis at the Company's facility. On October 8, 2019, the Company was granted licenses to cultivate, process and sell cannabis pursuant to the Cannabis Act (Bill C-45). On June 4, 2021, Canary received its Sales License amendment from Health Canada.

#### Accounts payable and accrued liabilities
Accounts payable amounting to $2,926,448 as of March 31, 2026, primarily represents consulting and construction services related to capital work in progress amounting to $99,109, interest on promissory notes and loans amounting to $1,276,624, and outstanding, accrued professional fees amounting to $905,179.

Accounts payable amounting to $2,637,973 as of December 31, 2025, primarily represents consulting and construction services related to fixed asset additions amounting to $100,794, interest on promissory notes and loans amounting to $1,203,273, outstanding and accrued professional fees amounting to $940,235.

#### Payable to related parties
As of March 31, 2026, the Company had $10,423,034 payable to related parties as compared to $10,361,576 as of December 31, 2025. The balance primarily represents loans provided by the Company's shareholder and a related party, CLI, management services fee outstanding to the managers of the company, and outstanding amount of $65,000 to be paid to a former shareholder of CannaKorp as part of the settlement agreement.

#### Convertible promissory notes payable
Interest amounting to $9 was accrued for the three months ended March 31, 2026 (March 31, 2025: $10).

The principal amount outstanding as of March 31, 2026 and December 31, 2025 was $480. At both reporting dates, the entire balance was current.

***Statement of Operations – For the three months ended March 31, 2026 and 2025:***

#### Revenue
**The Company generated revenue of $879,442 during the quarter ended in 2026 while $1,400,439 in the comparable period of 2025. The Company revenue represents the sale of cannabis product and the revenue was concentrated to three customers that represent over 10% of total revenue.**

[**Table of Contents**](#TOC)

#### Expenses
The Company's expenses are classified primarily into advisory and consultancy fees, management fees, salaries and wages, legal and professional fees, depreciation expense and office and general expense. The decrease in operating expenses during the current quarter ended compared to comparable prior quarter ended is mainly due to decrease in legal and professional fees, office and general expenses and advisory and consultancy fee in the current period.

Expenses primarily represented consulting fees of $25,260 (2025: $53,842), management fees of $89,951 (2025: $152,473), legal and professional charges of $34,310 (2025: $50,185) comprising legal, review, accounting and Edgar agent fee, depreciation expense amounting to $229,653 (2025: $218,476), operating lease expense of $44,855 (2025: $49,237) and office and general expenses of $77,645 (2025: $93,040).

Changes in other income and expenses were due to: (1) increase in the principal balance led to increased interest expense; and (2) and there is exchange income during the quarter due to favorable exchange rate.

Other income and expenses comprised, change in fair value of derivative and warranty liability amounting to negative $43 (2025: negative $10,402), interest and bank charges amounting to $288,249 (2025: $250,766), exchange gain of $35,030 (2025: loss of $995), and debt issuance cost of nil (2025: $11,689).

#### Liquidity and Capital Resources
As of March 31, 2026, the Company had a working capital deficit of $11,342,944 (December 31, 2025: $11,052,097). The Company is actively seeking various financing opportunities to meet the deficit capital requirements.

Target Group has relied on equity financing and related party debt financing for our operations. The proceeds may not be sufficient to effectively develop our business to the fullest extent to allow us to maximize our revenue potential, in which case, we will need additional capital.

The Company will need capital to allow us to invest in development, and it anticipates that its future operations will generate positive cash flows provided that it is successful in obtaining additional financing in the foreseeable future.

***Statement of Cash Flow – For the three months ended March 31, 2026 and 2025:***

*Operating activities*

Operating activities used cash of $93,665 compared to cash used of $570,005 for the corresponding period of the prior year. This is primarily due to the change in accounts receivable, inventory and accounts payable and accrued liabilities.

*Investing activities*

Investing activities used cash of $40,055 for the three months ended March 31, 2026 compared to $27,965 cash provided in the corresponding period of the prior year. This is due to the purchase of assets during the period.

*Financing activities*

Financing activities provided cash of $240,570 for the three months ended March 31, 2026 compared to cash used of $557,440 during the three months of 2025 this was due to the loan received from related party.

#### Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

[**Table of Contents**](#TOC)

#### Critical Accounting Policies
All critical accounting policies are described in the Company's Form 10-K for the year ended December 31, 2025.

#### Subsequent Events
**The Company's management has evaluated subsequent events through the date the unaudited condensed consolidated interim financial statements were issued, pursuant to the requirements of ASC 855 and has no subsequent events to report.**

#### Description of Property
The Company does not own any properties at this time, nor any agreements to acquire any properties.

The Company's principal executive office is located at 20 Hempstead Drive, Hamilton, Ontario, Canada.

The Company's subsidiary, Canary, leases a 44,000 square foot facility located in Norfolk County, Ontario to produce medical and recreational cannabis.

#### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Smaller reporting companies are not required to provide the information required by this item.

#### ITEM 4. CONTROLS AND PROCEDURES

#### Evaluation of disclosure controls and procedures
Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 ("Exchange Act"), we have carried out an evaluation, with the participation of our management, including the Company's principal executive officer and principal financial officer of the effectiveness of the Company's disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of March 31, 2026 to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the periods specified in the SEC's rules and forms and (ii) is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

#### Changes in internal controls
No change in our system of internal control over financial reporting occurred during the three months ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

[**Table of Contents**](#TOC)

#### PART II – OTHER INFORMATION

#### ITEM 1. LEGAL PROCEEDINGS
During the year ended December 31, 2019, a terminated employee of Canary filed a lawsuit against the Company amounting to approximately USD $1,529,837 (alleged damages of CAD $2,100,000) in Ontario, Canada. Currently, the Company is defending its position and believes that the ultimate decision will be in favor of the Company.

A complaint for damages of USD $150,000 was filed against CannaKorp by the former Chief Financial Officer of CannaKorp for outstanding professional fees. No claim has been registered. The management is of the view that no material losses will arise in respect of the legal claim at the date of this report.

During the year ended December 31, 2020, a claim for damages of approximately USD $95,271 (alleged damages of CAD $130,778) was filed against Canary by a vendor for breach of contract. The management is of the view that no material losses will arise in respect of the legal claim at the date of this report. As of December 31, 2025, $100,795 (CAD 138,150) has been recorded in the Canary's payable based on past accruals. Due to the uncertainty of timing and the amount of estimated future cash flows, if any, relating to this claim, no further amount has been recognized.

#### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.

#### ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.

#### ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

#### ITEM 5. OTHER INFORMATION
None.

[**Table of Contents**](#TOC)

#### ITEM 6. EXHIBITS
Exhibits:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**ExhibitNo.** | <br>**Description** | **Form** | **Exhibit** | **FilingDate** |
| 2.1 | [Asset Acquisition Agreement](https://www.sec.gov/Archives/edgar/data/1586554/000114420414073261/v395275_ex2-1.htm) | 8-K | 2.1 | 12/11/14 |
| 2.1.1 | [Agreement and Plan of Share Exchange dated June 27, 2018 with Visava Inc.](https://www.sec.gov/Archives/edgar/data/1586554/000114420418037070/tv497881_ex2-1.htm) | 8-K | 2.1 | 07/03/18 |
| 2.1.2 | [Agreement and Plan of Share Exchange dated January 25, 2019 with CannaKorp Inc. and David Manly, as Stockholder Representative](https://www.sec.gov/Archives/edgar/data/1586554/000114420419003413/tv511883_ex2-1.htm) | 8-K | 2.1 | 01/29/19 |
| 3(i)(a) | [Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1586554/000102143213000259/certofincriverrun.txt) | 10-12G | 3.1 | 09/30/13 |
| 3(i)(a) | [Amended Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1586554/000141057822000428/tmb-20211231xex3d1.htm) | 10-K | 3(i)(a) | 03/18/22 |
| 3(i)(a) | [Certificate of Amendment](https://www.sec.gov/Archives/edgar/data/1586554/000114420416128659/v450786_ex3i.htm) | 8-K | 3(i) | 10/20/16 |
| 3(i)(a) | [Certificate of Amendment](https://www.sec.gov/Archives/edgar/data/1586554/000114420417020175/v464174_ex3-i.htm) | 8-K | 3(i) | 04/12/17 |
| 3(i)(a) | [Certificate of Amendment](https://www.sec.gov/Archives/edgar/data/1586554/000114420417035873/v470422_ex3-i.htm) | 8-K | 3(i) | 07/06/17 |
| 3(i)(a) | [Certificate of Amendment](https://www.sec.gov/Archives/edgar/data/1586554/000114420417055425/tv478294_ex3-i.htm) | 8-K | 3(i) | 11/01/17 |
| 3(i)(a) | [Certificate of Amendment](https://www.sec.gov/Archives/edgar/data/1586554/000114420418051751/tv503903_ex3-i.htm) | 8-K | 3(i) | 10/01/18 |
| 3.2 | [Bylaws](https://www.sec.gov/Archives/edgar/data/1586554/000102143213000259/bylawriverrun.txt) | 10-12G | 3.2 | 09/30/13 |
| 4.1 | [Description of Capital Stock](https://www.sec.gov/Archives/edgar/data/1586554/000110465920046312/tm205296d1_ex4-1.htm) | 10-K | 4.1 | 04/14/20 |
| 10.1 | [Form of Securities Purchase Agreement-Blackbridge Capital Growth Fund, LLC](https://www.sec.gov/Archives/edgar/data/1586554/000114420417018267/v462088_ex10-1.htm) | 10-K | 10.1 | 03/31/17 |
| 10.2 | [Form of Convertible Promissory Note](https://www.sec.gov/Archives/edgar/data/1586554/000114420417018267/v462088_ex10-2.htm) | 10-K | 10.2 | 03/31/17 |
| 10.3 | [Form of Convertible Promissory Note](https://www.sec.gov/Archives/edgar/data/1586554/000114420417018267/v462088_ex10-3.htm) | 10-K | 10.3 | 03/31/17 |
| 10.4 | [Form of Convertible Promissory Note](https://www.sec.gov/Archives/edgar/data/1586554/000114420417018267/v462088_ex10-4.htm) | 10-K | 10.4 | 03/31/17 |
| 10.5 | [Form of Securities Purchase Agreement-Crown Bridge Partners, LLC](https://www.sec.gov/Archives/edgar/data/1586554/000114420417018267/v462088_ex10-5.htm) | 10-K | 10.5 | 03/31/17 |
| 10.6 | [Form of Convertible Promissory Note](https://www.sec.gov/Archives/edgar/data/1586554/000114420417018267/v462088_ex10-6.htm) | 10-K | 10.6 | 03/31/17 |
| 10.10 | [Securities Purchase Agreement-Power Up Lending Group Ltd.](https://www.sec.gov/Archives/edgar/data/1586554/000114420418017620/tv489257_ex10-10.htm) | 10-K | 10.10 | 03/28/18 |
| 10.11 | [Convertible Promissory Note-Power-Up Lending Group Ltd.](https://www.sec.gov/Archives/edgar/data/1586554/000114420418017620/tv489257_ex10-11.htm) | 10-K | 10.11 | 03/28/18 |
| 10.12 | [Securities Purchase Agreement-Power Up Lending Group Ltd.](https://www.sec.gov/Archives/edgar/data/1586554/000114420418017620/tv489257_ex10-12.htm) | 10-K | 10.12 | 03/28/18 |
| 10.13 | [Convertible Promissory Note-Power-Up Lending Group Ltd.](https://www.sec.gov/Archives/edgar/data/1586554/000114420418017620/tv489257_ex10-13.htm) | 10-K | 10.13 | 03/28/18 |
| 10.14 | [Securities Purchase Agreement-Power Up Lending Group Ltd. dated December 24, 2018](https://www.sec.gov/Archives/edgar/data/1586554/000114420419017380/tv517506_ex10-14.htm) | 10-K | 10.14 | 04/01/19 |

---

[**Table of Contents**](#TOC)

10.15 [Convertible Promissory Note-Power-Up Lending Group Ltd. dated December 24, 2018](https://www.sec.gov/Archives/edgar/data/1586554/000114420419017380/tv517506_ex10-15.htm) 10-K 10.15 04/01/19

10.16 [Distribution, Collaboration and Licensing Agreement dated December 6, 2018 between Target Group Inc, Canary Rx Inc., Serious Seeds B.V. and Simon Smit](https://www.sec.gov/Archives/edgar/data/1586554/000114420419017380/tv517506_ex10-16.htm) 10-K 10.16 04/01/19

10.17 [Licensed Producer/Licensed Processor Sales Agency Agreement dated December 13, 2018 with Cannavolve Inc.](https://www.sec.gov/Archives/edgar/data/1586554/000114420419017380/tv517506_ex10-17.htm) 10-K 10.17 04/01/19

10.18 [Exclusive License Agreement dated August 8, 2019 with cGreen Inc.](https://www.sec.gov/Archives/edgar/data/1586554/000114420419039341/tv527465_ex2-1.htm) 8-K 2.1 08/13/19

10.19 [Purchase, Licensing and Purchase Agreement dated September 17, 2019 between CannaKorp, Inc. and Nabis Arizona LLC](https://www.sec.gov/Archives/edgar/data/1586554/000114420419045183/tv529732_ex10-1.htm) 8-K 10.1 09/19/19

10.20 [Loan Agreement dated December 20, 2019 with Jerry Zarcone](https://www.sec.gov/Archives/edgar/data/1586554/000110465920046312/tm205296d1_ex10-20.htm) 10-K 10.20 04/14/20

10.21 [First Amending Agreement dated March 11, 2020 with Jerry Zarcone](https://www.sec.gov/Archives/edgar/data/1586554/000110465920070354/tm2014644d1_ex10-21.htm) 10-Q 10.21 06/05/20

10.22 [Second Amending Agreement dated April 30, 2020 with Jerry Zarcone](https://www.sec.gov/Archives/edgar/data/1586554/000110465920092838/tm2024712d1_ex10-22.htm) 10-Q 10.22 08/10/20

10.23 [Third Amending Agreement dated May 15, 2020 with Jerry Zarcone](https://www.sec.gov/Archives/edgar/data/1586554/000110465920092838/tm2024712d1_ex10-23.htm) 10-Q 10.23 08/10/20

10.24 [Promissory Note Between Target Group Inc. and Frank Zarcone](https://www.sec.gov/Archives/edgar/data/1586554/000110465920092838/tm2024712d1_ex10-24.htm) 10-Q 10.24 08/10/20

10.25 [Joint Venture Agreement between Canary Rx Inc. and 9258159 Canada, Inc. dated May 14, 2020](https://www.sec.gov/Archives/edgar/data/1586554/000110465920092838/tm2024712d1_ex10-25.htm) 10-Q 10.25 08/10/20

10.26 [Debt Purchase and Assignment Agreement dated June 15, 2020](https://www.sec.gov/Archives/edgar/data/1586554/000110465920096537/tm2028923d1_ex10-1i.htm) 8-K 10.1(i) 08/18/20

10.27 [Amendment dated August 14, 2020 to Debt Purchase and Assignment Agreement](https://www.sec.gov/Archives/edgar/data/1586554/000110465920096537/tm2028923d1_ex10-1ii.htm) 8-K 10.1(ii) 08/18/20

10.29 [Fourth Amending Agreement dated June 12, 2021](https://www.sec.gov/Archives/edgar/data/1586554/000141057822002980/tmb-20220930xex10d29.htm) 10-Q 10.29 11/7/22

10.30 [Fifth Amending Agreement dated February 16, 2022](https://www.sec.gov/Archives/edgar/data/1586554/000141057822002980/tmb-20220930xex10d30.htm) 10-Q 10.30 11/7/22

10.31 [Sixth Amending Agreement dated October 18, 2022](https://www.sec.gov/Archives/edgar/data/1586554/000141057822002980/tmb-20220930xex10d31.htm) 10-Q 10.31 11/7/22

10.32 [Seventh Amending Agreement dated February 16, 2023](https://www.sec.gov/Archives/edgar/data/1586554/000141057823000922/tmb-20230331xex10d32.htm) 10-Q 10.32 5/8/23

10.33 [Eighth Amending Agreement dated March 28, 2023](https://www.sec.gov/Archives/edgar/data/1586554/000141057823000922/tmb-20230331xex10d33.htm) 10-Q 10.33 5/8/23

10.34 [Seventh Amending Agreement dated February 16, 2023 (corrected)](https://www.sec.gov/Archives/edgar/data/1586554/000141057823001629/tmb-20230630xex10d34.htm) 10-Q 10.34 8/9/23

10.35 [Ninth Amending Agreement dated November 7, 2023](https://www.sec.gov/Archives/edgar/data/1586554/000141057823002246/tmb-20230930xex10d35.htm) 10-Q 10.35 11/08/23

10.36 [Tenth Amending Agreement dated August 16, 2024](https://www.sec.gov/Archives/edgar/data/1586554/000141057824001793/tmb-20240930xex10d36.htm) 10-Q 10.36 11/07/24

10.37 [Eleventh Amending Agreement dated August 11, 2025](https://www.sec.gov/Archives/edgar/data/1586554/000141057825001696/tmb-20250630xex10d37.htm) 10-Q 10.37 8/12/25

10.38 [Twelfth Amending Agreement dated January 25, 2026](tmb-20260331xex10d38.htm) 10-Q 10.38 5/15/26

[**Table of Contents**](#TOC)

---

| | |
|:---|:---|
| 31.1\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tmb-20260331xex31d1.htm) |
| 31.2\* | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tmb-20260331xex31d2.htm) |
| 32.1\* | [Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tmb-20260331xex32d1.htm) |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
| Exhibit 104 | Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |

---

\* Filed herewith.

[**Table of Contents**](#TOC)

#### SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | TARGET GROUP INC. | TARGET GROUP INC. |
| Dated: May 15, 2026 | By: | */s/ Anthony Zarcone* |
|  |  | Chief Executive Officer, and Director |
| Dated: May 15, 2026 | By: | */s/ Barry Alan Katzman* |
|  |  | Director |
| Dated: May 15, 2026 | By: | */s/ Saul Niddam* |
|  |  | Director |

---

## Exhibit 10.38

**Exhibit 10.38**

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20260331xex10d38g001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 1 - TWELFTH AMENDING AGREEMENT THIS AGREEMENT made as of the 25 day of January, 2026 B E T W E E N : JERRY ZARCONE (hereinafter referred to as "Jerry") - and – TARGET GROUP INC. (hereinafter referred to as "TGI") - and – CANARY RX INC. (hereinafter referred to as "Canary") - and – VISAVA INC. (hereinafter referred to as "Visava") - and – CANNAKORP INC. (hereinafter referred to as "Cannakorp", which together with Visava and Canary shall be collectively referred to as the "Subsidiaries") WHEREAS: A. Jerry and TGI entered into a Loan Agreement made as of the 20th day of December, 2019 (the "Loan Agreement"), which Loan Agreement has been amended and extended by various amending and extending agreements from time to time the most recent of is the Eleventh Amending Agreement made as of the 11th day of August, 2025 (collectively, the "FAEA"); B. All capitalized terms shall have the meanings ascribed to them in the FAEA unless otherwise defined herein; Docusign Envelope ID: 2BE13BF8-473F-450E-A95E-B7CBFCF35899 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20260331xex10d38g002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 2 - C. The parties are desirous of further amending the Loan Agreement upon the terms and provisions of this Agreement. NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the respective covenants and agreements hereinafter contained and the sum of One Dollar ($1.00) now paid by the parties hereto each to the other (the receipt and sufficiency of which is hereby acknowledged by each of the parties hereto), the parties hereto agree as follows: 1. The parties hereby declare and confirm that the Recitals are true and accurate and form integral terms and provisions of this Agreement. 2. The Loan be and same is hereby increased by the principal amount of a further Three Hundred and Thirty Thousand ($330,000.00) Dollars (CDN) (the "Sixth Tranche") upon the following terms and provisions: (a) The Sixth Tranche shall be subject to a Lender's Fee in the amount of Thirty-Three Thousand ($33,000.00) Dollars (CDN), which shall be deducted and paid from the advance thereunder; (b) The Sixth Tranche shall be subject to a rate of interest equal to 3.0416% per month (being 43.26% per annum), calculated monthly, not in advance; (c) All principal and interest owing and accrued under the Sixth Tranche shall be repayable on December 31, 2026, provided that when in not in default, the Sixth Tranche may be repaid in full upon no less than three (3) months' written notice thereof; (d) For further clarity, all monies owing and the performance of all other covenants and obligations by Sixth Tranche be and same shall be guaranteed by the Subsidiaries and secured under the Security; and (e) Contemporaneous with the execution and delivery of this Agreement, TGI and the Subsidiaries shall reimburse Jerry for all legal costs and expenses in respect of the Loan including, without limitation, any demands thereof and the negotiation, drafting and execution of this Agreement. 3. The parties acknowledge and agree that, at the request of TGI, Jerry may, from time to time in his sole and absolute discretion, make further loans to TGI in an aggregate principal amount not to exceed Five Hundred Thousand Dollars ($500,000.00), subject to a ten percent (10%) lender's fee and bearing interest at the rate applicable to the Sixth Tranche, as set forth herein. For greater certainty, any such further advances pursuant to this Section 3 shall be consolidated into, and form part of, the Sixth Tranche. 4. TGI and the Subsidiaries shall execute, deliver, and, if applicable, register within a reasonable time following presentation thereof by Jerry or his counsel (but in no event more than five (5) business days following such presentation) and shall also promptly do or cause Docusign Envelope ID: 2BE13BF8-473F-450E-A95E-B7CBFCF35899 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20260331xex10d38g003.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 3 - to be done all other acts and things, execute and deliver or cause to be executed and delivered all agreements and documents and provide any further assurances, undertakings and information in order to give full effect to this Agreement. 5. Except as modified by this Agreement, the Loan Agreement shall be unamended and shall be and shall remain in full force and effect. Also, to the extent that any term or provision of this Agreement conflicts with any term or provision of the Loan Agreement, the terms and provision of this Agreement shall prevail. 6. This Agreement may be executed by the parties in separate counterparts each of which when so executed and delivered to each other shall be deemed to be and shall be read as a single agreement among the parties. 7. This Agreement is governed by and is to be construed and interpreted in accordance with, the laws of the Province of Ontario and the laws of Canada applicable in that Province. 8. This Agreement constitutes the entire agreement between the parties pertaining to the subject matter of this Agreement and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the parties, and there are no representations, warranties or other agreements between the parties in connection with the subject matter of this Agreement except as specifically set out in this Agreement. [signatures intentionally on next page] Docusign Envelope ID: 2BE13BF8-473F-450E-A95E-B7CBFCF35899 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20260331xex10d38g004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 4 - Each of the parties has executed and delivered this Agreement as of the date first above written. SIGNED IN THE PRESENCE OF)))) Witness) JERRY ZARCONE TARGET GROUP INC. Per: Name: Saul Niddam Position: Director Name: Anthony Zarcone Position: Director _____________________________________ Name: Barry Katzman Position: Director We have authority to bind the Corporation CANARY RX INC. Per: Name: Anthony Zarcone Position: President & CEO I have authority to bind the Corporation VISAVA INC. Per: Name: Anthony Zarcone Position: President & CEO I have authority to bind the Corporation CANNAKORP INC. Per: Docusign Envelope ID: 2BE13BF8-473F-450E-A95E-B7CBFCF35899 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tmb-20260331xex10d38g005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- 5 - Name: Saul Niddam Position: CEO I have authority to bind the Corporation Docusign Envelope ID: 2BE13BF8-473F-450E-A95E-B7CBFCF35899 |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO SECTION 302**

I, Anthony Zarcone, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Form 10-Q of Target Group Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the unaudited condensed consolidated interim financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of unaudited condensed consolidated interim financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report is any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Dated: May 15, 2026 | */s/ Anthony Zarcone* |
|  | Chief Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO SECTION 302**

I, Anthony Zarcone, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Form 10-Q of Target Group Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the unaudited condensed consolidated interim financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of unaudited condensed consolidated interim financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and

&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report is any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Dated: May 15, 2026 | */s/ Anthony Zarcone* |
|  | Principal Financial Officer |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANTTO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, the undersigned officer of Target Group Inc. (the "Company"), hereby certify that:

The Report on Form 10-Q for the for the three months ended March 31, 2026 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly represents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Dated: May 15, 2026 | By: | */s/ Anthony Zarcone* |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |
|  |  | (Principal Financial Officer) |

---

------